CTOs on the Move

Flexicon America

www.flexiconamerica.com

 
Flexicon America is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Mitsubishi Tanabe Pharma America

At Mitsubishi Tanabe Pharma America (MTPA), we believe in helping people who are struggling with serious and debilitating diseases.

Falks Woodland Pharmacy

Falks Woodland Pharmacy, Inc. is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Newlink Genetics

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.

Genactis

Genactis is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.